30 closest matches · ranked by relevance
Melanoma · Metastatic Melanoma · Solid Tumor
Primary: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Deaths — 4; 3; 3; 3 Participants
Unspecified Adult Solid Tumor, Protocol Specific
Primary: Percentage of Patients Tolerating Re-escalated Dose of Sorafenib for 28 Days Without Dose Interruption or De-escalation for Toxicity — 11 Participants
Solid Tumor · Leiomyosarcoma · Osteosarcoma
Primary: Changes in Phospho-Chk1 Levels in Biopsy Specimens — 156; 196; 89; 84 percent change
Advanced/Metastatic Solid Malignancies
Primary: Overall Response Rate (Confirmed) — 1; 1 Participants
Advanced Solid Tumor · Lung Cancer · Pancreas Cancer
Primary: Safety and Tolerability Assessment of CNSI-Fe(II) — 0; 0; 1; 0 Participants
Carcinoma
Primary: Overall Survival — 13.43; 7.62 months
Tumors
Primary: Dose-Escalation Phase: Number of Patients With Dose-Limiting Toxicities (DLTs) — 0; 1; 0; 1 Participants
Carcinoma, Non-Small-Cell Lung
Primary: Best Disease Response After a Maximum of Six Cycles. — 0; 23; 23; 6 Participants
Solid Malignancy · Solid Tumor
Primary: Response Rate (RR) — 1 Participants
Part 1 · MELANOMA · SCCHN
Primary: Percentage of Participants With Dose-Limiting Toxicities (DLT) - Part 1 — 0; 0; 0; 0 Percentage of Participants
Breast Cancer · Melanoma
Primary: Concordance of Blue Dye and Lymphoseek — 1.0000 Proportion of Lymph Nodes
Solid Tumors · Cancer
Primary: Number of Subjects Experienced Any Dose-Limiting Toxicity (DLT) Over the First Cycle - Day 1 to 21 — 2; 6; 0; 6 Subjects
Tumors
Primary: Non-progression Rate (NPR) at 18 Weeks — 26.8; 44.4; 29.6; 40.0 percentage of participants
Advanced Solid Tumors
Primary: Objective Response Rate (ORR) Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Escalation and Dose Expansion Phases) — 0…
Malignant Peripheral Nerve Sheath Tumors (MPNST) · Sarcoma
Primary: Number of Dose Limiting Toxicities of Ganetespib When Administered in Combination With Sirolimus. — 0; 1 DLTs
Solid Tumors
Primary: Dose Escalation Cohort (Excluding Once Weekly Avelumab 10 mg/kg Cohort): Number of Participants Experiencing Dose Limiting Toxicities (DLTs) — 0; 0; 0; 1 Participants
Cancer
Primary: Response and Progression Will be Evaluated in This Study Using the New International Criteria Proposed by the Response Evaluation Criteria in Solid Tumors (RECIST)…
Advanced Solid Tumors · Advanced Recurrent Ovarian Tumors
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 1; 1; 2; 1 Participants
Malignant Melanoma
Primary: Maximum Tolerated Dose (MTD) of IMC-20D7S — 20 mg/kg q2w
Neoplasms
Primary: Number of Participants With Dose-limiting Toxicities (DLT) in Part 1 — 0; 0; 1; 1 participants
Malignant Peripheral Nerve Sheath Tumors · Neurofibromatosis 1
Primary: Clinical Benefit Rate of Selumetinib in Combination With Sirolimus in Patients With Unresectable or Metastatic NF1 Associated or Sporadic MPNST. — 0.095 Proportion
Solid Tumor
Primary: The Primary Objective of the Dose Finding Component is to Determine the Maximum Tolerated Dose (MTD) of HCW9218 — 1.2 mg/kg
Oncology · MET Gene Amplification · NSCLC
Primary: Part 1: Occurrence of DLTs During Cycle 1 of Sym015 Administration — 0; 0; 0; 0 Number of DLTs
Ovarian Cancer Stage IIIC · Ovarian Cancer Stage IV
Primary: Safety: Number of Participants With Freedom From Device and Procedure-related Major Adverse Events — 18 Participants — p=0.1309
Advanced or Metastatic Solid Tumors
Primary: Objective Response Rate ( ORR ) — 5.6; 0.0; 0.0; 11.9 Percentage of Participants — p=0.0309
High Grade Malignant Neuroendocrine Carcinoma (Diagnosis)
Primary: Overall Response Rate (ORR) — 7; 5 percentage of participants
Neoplasms
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) — 4; 4; 4; 4 Participants
Melanoma
Primary: Association of Baseline C11-AMT PET SUV Max Value With Objective Response — 6; 6; 1; 13 Participants — p=0.08
Liposarcoma · Leiomyosarcoma · Fibrosarcoma
Primary: Number of Participants With Overall Response (OR) — 1 participants
Sarcoma
Primary: Patients With Response (Confirmed Complete, and Partial) With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor When Treated With Erlotinib. — 0…